Hotpennystocknews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angeles, CA -- (SBWIRE) -- 01/24/2014 -- Hotpennystocknews.com issues special report on - IntelGenx (IGXT)
IntelGenx (IGXT) is a Montreal based company devoted to developing its novel and innovative proprietary technologies for enhanced drug delivery.
Their business strategy is to apply our proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy.
IntelGenx is capable, through itself and strategic partners, of offering its partners full service pharmaceutical development from formulation development, clinical development and regulatory activities to manufacturing and packaging.
IntelGenx’s highly qualified team has the capability to work with new chemical entities (NCEs) or established therapeutic active pharmaceutical ingredients (APIs) where the use of innovative new drug delivery systems offer significant competitive advantage or the opportunity for product extension and life cycle management.
IntelGenx has three proprietary delivery platforms, including an immediate release oral film, VersaFilm, a mucoadhesive tablet, AdVersa and multilayer controlled release tablet, VersaTab. IntelGenx has an aggressive product development initiative that primarily focuses on addressing unmet market needs. Their rapidly growing product pipeline consists of products at various stages of development from inception to commercialization.
IGXT, through its cutting edge formulation platforms, has developed a broad and diverse product portfolio, including products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products.
IGXT added 10.50% recently, in the current trading session, at $0.884 with a total volume of 1.52M shares. The stock, on average, trades on a volume of 1.29M shares. It floated in a range of $0.81 to $0.93 during the recent trading session, with a beta value of 32.25. Its market capitalization now moved to about $47.71M. In the past 52 weeks, the share price has not declined below $0.45 and failed to cross $0.93.
For How Long IGXT will Attract Investors? Find out via this report.
Neither Hotpennystocknews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Hotpennystocknews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.Hotpennystocknews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Hotpennystocknews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in.
Read Full disclaimer at:http://www.hotpennystocknews.com/disclaimer.php
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)